About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Linvoseltamab
- Company
- Regeneron Pharmaceuticals
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 17 recruiting
Efficacy results: Not yet reported
17 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Oct 29, 2026
Find a Clinical Trial Near Me
See recruiting studies for Linvoseltamab and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Not yet reported, Not yet reported Regeneron Pharmaceuticals 387 participants Est. completion 2033-06-16 40 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Not yet reported Regeneron Pharmaceuticals 317 participants Est. completion 2032-03-24 42 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Not yet reported Regeneron Pharmaceuticals 410 participants Est. completion 2033-04-19 159 sites Stand-aloneOther conditions: Relapsed Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT05828511
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Not yet reported, Not yet reported Regeneron Pharmaceuticals 149 participants Est. completion 2035-11-02 32 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06140524
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Not yet reported Regeneron Pharmaceuticals 116 participants Est. completion 2032-05-18 39 sites Stand-aloneOther conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)View official trial listing → -
Recruiting NCT NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Not yet reported, Not yet reported Regeneron Pharmaceuticals 220 participants Est. completion 2035-02-20 21 sites Stand-aloneOther conditions: Relapsed/Refractory Systemic Light Chain AmyloidosisView official trial listing → -
Recruiting NCT NCT06376526
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Not yet reported Dickran Kazandjian, MD 150 participants Est. completion 2029-08-31 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06669247
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Regeneron Pharmaceuticals 186 participants Est. completion 2035-11-01 9 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06910124
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Not yet reported Dickran Kazandjian, MD 32 participants Est. completion 2032-12-02 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Not yet reported European Myeloma Network B.V. 1000 participants Est. completion 2036-12 59 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07053436
Horizon Two: HR NDMM (MMRC-100)
Not yet reported Multiple Myeloma Research Consortium 300 participants Est. completion 2035-10-12 12 sites Stand-aloneOther conditions: High Risk Newly Diagnosed Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07181941
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Fred Hutchinson Cancer Center 30 participants Est. completion 2028-06-30 1 site Stand-aloneOther conditions: Recurrent Multiple Myeloma, Refractory Multiple MyelomaView official trial listing → -
Recruiting NCT NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Not yet reported Regeneron Pharmaceuticals 915 participants Est. completion 2034-08-23 44 sites Stand-aloneOther conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Not yet reported Regeneron Pharmaceuticals 270 participants Est. completion 2033-07-27 27 sites Stand-aloneOther conditions: High Risk Smoldering Multiple Myeloma (HR-SMM)View official trial listing → -
Recruiting NCT NCT07455851
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Not yet reported, Not yet reported Regeneron Pharmaceuticals 150 participants Est. completion 2033-09-30 8 sites Stand-aloneOther conditions: Relapsed Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT07609940
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Not yet reported Regeneron Pharmaceuticals 30 participants Est. completion 2028-12-06 7 sites Stand-aloneOther conditions: Relapsed/Refractory Multiple Myeloma (RRMM)View official trial listing → -
Recruiting NCT NCT07624513
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
Not yet reported Dana-Farber Cancer Institute 720 participants Est. completion 2038-03-01 3 sites Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Approved For Marketing NCT NCT05164250
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron PharmaceuticalsOther conditions: Multiple MyelomaView official trial listing → -
Active, not recruiting NCT NCT05955508
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Not yet reported Regeneron Pharmaceuticals 40 participants Est. completion 2033-01-25 17 sites Stand-aloneOther conditions: Smoldering Multiple Myeloma (SMM)View official trial listing → -
Active, not recruiting NCT NCT06369467
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
Not yet reported Regeneron Pharmaceuticals 6 participants Est. completion 2027-08-31 5 sites Stand-aloneOther conditions: Food AllergyView official trial listing → -
Available NCT NCT06631677
Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab
Regeneron PharmaceuticalsOther conditions: Food AllergyView official trial listing → -
Not yet recruiting NCT NCT07009899
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
Not yet reported Medical College of Wisconsin 34 participants Est. completion 2029-02-01 1 site Stand-aloneOther conditions: Multiple MyelomaView official trial listing → -
Withdrawn NCT NCT07428369
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Not yet reported, Not yet reported Regeneron Pharmaceuticals Est. completion 2038-05-21 Stand-aloneOther conditions: Multiple Myeloma (MM)View official trial listing → -
Not yet recruiting NCT NCT07474961
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Not yet reported Anne Louise Tølbøll Sørensen 400 participants Est. completion 2036-12 5 sites Stand-aloneOther conditions: Waldenstrom Macroglobulinaemia, Multiple MyelomaView official trial listing → -
Not yet recruiting NCT NCT07901725
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
Not yet reported Regeneron Pharmaceuticals 382 participants Est. completion 2035-07-25 Stand-aloneOther conditions: Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIAView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Linvoseltamab, REGN5458, Lynozyfic™
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.